Rhythm Pharmaceuticals Publishes Study Titled ‘Pediatric Rare Genetic Causes of Obesity’ To ClinicalTrials.Gov Website
https://clinicaltrials.gov/ct2/show/NCT04966741
Rhythm Pharma Reports Positive CHMP Opinion For Setmelanotide For Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that the European